The Roche, Novartis and Kraft Group-backed, protein degradation-focused drug developer received $150m in series B funding and $20m in venture debt.

C4 Therapeutics, a US-based small molecule drug developer backed by diversified conglomerate Kraft Group and pharmaceutical firms Roche and Novartis, completed a $170m financing round yesterday. Investment firm Cobro Ventures and hedge fund Perceptive Advisors co-led the $150m series B equity portion of the round, which also featured undisclosed existing investors, while Perceptive Advisors also…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.